Carrier Oils in Cannabinoid Products

The part of the label most people skip

Flip any cannabinoid product around and look at the "other ingredients" line. Nine times out of ten you'll find one of the common carrier oils listed, usually something like medium-chain triglyceride oil, hemp seed oil, or sunflower oil, tucked quietly beneath the active ingredient. Most people read straight past it. I'd argue that's a mistake, because the carrier isn't just packaging: it has a measurable influence on how cannabinoids behave once they're inside the body.

In pharmaceutical language, a carrier oil is an excipient, an ingredient that isn't the active substance but that shapes how the product dissolves, absorbs, tastes, pours and keeps. The active ingredient gets the attention, yet the excipient decides much of what happens to it between the bottle and the bloodstream. If you want the formal terminology, our glossary entry on the active pharmaceutical ingredient draws the line between the two.

This piece covers the chemistry of why that is, how different oils compare, and what the published research actually says, along with its honest limitations. Nothing here is a recommendation to use any product; it is an explanation of how formulation works.

Why cannabinoids need carrier oils at all

Cannabinoids like cannabidiol (CBD) and tetrahydrocannabinol (THC) are highly lipophilic molecules. That's a technical way of saying they dissolve readily in fats and oils, but very poorly in water. The human gut, however, is a largely aqueous environment. Without a lipid vehicle to keep a cannabinoid in solution and facilitate absorption across the intestinal wall, a significant proportion of an oral dose would pass through largely intact.

This is directly tied to the concept of bioavailability; the fraction of an administered substance that reaches systemic circulation in an active form. Oral cannabinoid bioavailability is notoriously variable, partly because of first-pass metabolism in the liver, and partly because of how well the initial absorption step goes in the small intestine. Carrier oils help with the latter. Our articles on the bioavailability of cannabinoids and first-pass metabolism cover each half of that picture in more detail.

The mechanism involves the lymphatic transport pathway. When dietary fats are digested, they're packaged into structures called chylomicrons, which are absorbed via intestinal lymphatics rather than the portal vein. Lipophilic drugs and plant compounds riding alongside dietary lipids can, to varying degrees, hitch a ride on this pathway, partially bypassing the liver on their first pass through the body. The degree to which this occurs depends on the chain length and saturation profile of the fatty acids in the carrier.

One common mistake is to treat the carrier as a passive solvent, as though any oil would do the same job. The lymphatic route is the reason that assumption falls down. Two oils can both dissolve a cannabinoid perfectly well in the bottle and still behave differently once digestion starts.

Chain length matters more than most labels let on

Fatty acids are classified by the number of carbon atoms in their chain: short-chain (fewer than 6 carbons), medium-chain (6–12), and long-chain (more than 12). This distinction isn't just biochemistry trivia, it affects the route of absorption. A triglyceride, the main form of fat in these oils, is simply three fatty acids attached to a glycerol backbone, so the chain length of those three fatty acids defines how the whole molecule is handled in the gut.

Medium-chain triglycerides (MCTs), derived most commonly from coconut or palm kernel oil, are absorbed relatively rapidly and tend to be transported via the portal vein rather than the lymphatic system. That means they're efficient energy sources, but they may offer less advantage for lymphatic co-transport of lipophilic compounds compared to long-chain fats.

Long-chain triglycerides (LCTs), found in oils like olive oil, sunflower oil, and sesame oil, are more likely to stimulate chylomicron formation and lymphatic uptake. A 2019 study published in Drug Delivery (Zgair et al., referenced below) examined exactly this distinction with cannabinoids, finding that the fatty acid composition of the lipid vehicle influenced cannabinoid absorption profiles in rat models. The human data is thinner and the extrapolations need to be made carefully; animal pharmacokinetic findings don't always translate cleanly, but the directional finding is consistent with broader lipid-drug co-administration literature.

Hemp seed oil sits in an interesting middle position. It's predominantly long-chain polyunsaturated fatty acids (linoleic and alpha-linolenic acid), and it also contains minor amounts of cannabinoids and terpenes native to the hemp plant. Whether those trace components contribute anything meaningful to a formulation is genuinely contested, and I'd be cautious about the more enthusiastic claims made for it without larger controlled trials.

The MCT question

MCT oil is a dominant carrier in many cannabinoid formulations, and I understand why: it's relatively odourless, has a light texture, and is shelf-stable. But the rationale isn't purely about bioavailability. MCT oil is also used because it's easy to work with at manufacturing scale, it has a long history of pharmaceutical use as an excipient, and it's well-tolerated by most people orally.

Those are practical virtues, and they are real ones. A carrier that stays clear, doesn't smell, and stays liquid at ordinary room temperatures makes for a more consistent product from batch to batch, and consistency is a quality attribute in its own right. Manufacturers aren't being careless when they choose MCT; they're weighing several things at once, and absorption is only one of them.

The trade-off is that MCTs may not optimally stimulate the lymphatic co-transport pathway compared to LCT-dominant oils. Some researchers have suggested that formulations designed for enhanced lymphatic uptake should lean toward long-chain saturated or monounsaturated fats. Whether that translates to a clinically meaningful difference in real-world cannabinoid products hasn't been definitively established in human trials. Honestly, the formulation science here is still catching up to commercial practice.

From absorption to the endocannabinoid system

Once absorbed, cannabinoids interact with receptors distributed throughout the body as part of the endocannabinoid system. The two primary receptor types, CB1 and CB2; are activated by endogenous ligands like anandamide as well as by phytocannabinoids. The efficiency of that interaction depends on how much active compound reaches the receptor site, which is a downstream consequence of absorption, and therefore, upstream, of formulation. For the signalling side of the story, see our piece on cannabinoid receptor signalling.

This matters more for some cannabinoids than others. Minor cannabinoids such as cannabigerol (CBG) appear in full-spectrum preparations at relatively low concentrations; any formulation factor that meaningfully shifts their bioavailability could, in principle, affect whether they reach physiologically relevant concentrations at all. The same logic applies to the minor compounds tracked in our glossary, from THCV to trace terpenes like beta-caryophyllene and linalool, which are themselves lipophilic and subject to similar absorption dynamics.

The phrase "in principle" is doing real work in that paragraph. It describes a plausible chain of reasoning, from carrier to absorption to concentration, not a demonstrated outcome for any particular product. Each link in that chain is a place where the evidence can be strong, weak or missing.

Oxidative stability: the shelf-life side of the equation

There's another reason carrier oil selection isn't trivial: oxidative stability. Polyunsaturated fats degrade faster under heat, light, and oxygen exposure than saturated or monounsaturated fats. The reason is structural. Each double bond in a fatty acid chain is a point where oxygen can attack, so the more double bonds an oil carries, the more vulnerable it is. An unstable carrier can generate lipid peroxidation products over time, which is a quality concern independent of the cannabinoid content.

Hemp seed oil, for all its appeal as a "whole plant" choice, has a relatively short shelf life compared to MCT or olive oil. Products using it typically need tighter storage recommendations and shorter use-by windows. This is a formulation constraint, not a criticism of hemp seed oil per se, just a real consideration that affects product quality over time, particularly relevant under Australian ambient temperatures in cities like Brisbane, where storage conditions outside of air conditioning can be harsh.

In my view this is the most underrated point in the whole topic, and it genuinely matters: a product that was well-formulated at manufacture can degrade significantly by the time it reaches a consumer if the carrier was poorly chosen for the storage context. Our article on the shelf life and storage of cannabinoid products goes further into what degradation looks like and why light-protective packaging matters.

Oxidation also isn't always visible. Rancid oils often smell or taste off, but early-stage peroxidation can be hard to detect by eye or nose, which is part of why use-by dates and storage statements on a label deserve attention rather than a glance.

What the regulatory picture looks like in Australia

In Australia, medicinal cannabis products; including oil-based formulations, are regulated by the Therapeutic Goods Administration (TGA) under the Therapeutic Goods Act 1989. Products containing THC are Schedule 8 controlled drugs under the Poisons Standard; most CBD products remain Schedule 4 prescription-only medicines. Access pathways include the Special Access Scheme and the Authorised Prescriber pathway. The TGA's own medicinal cannabis information is the authoritative place to confirm current rules.

Importantly, the TGA requires that therapeutic goods meet Good Manufacturing Practice (GMP) standards, which include specifications for excipients, the category that carrier oils fall into. The choice of carrier isn't purely a marketing decision for registered products; it's part of the dossier that gets assessed for quality and safety. Products listed on the Australian Register of Therapeutic Goods (ARTG) have undergone that scrutiny. Over-the-counter or imported products that haven't gone through that process sit in a very different regulatory position, and consumers should be aware of that distinction.

The practical upshot is about evidence of quality, not about any one oil being "approved". An excipient specification, a stability programme and a batch record are the kinds of documents that sit behind a registered product. Where a product has none of that behind it, a carrier oil named on the label tells you very little about how the formulation was actually tested. Related quality questions, such as contamination screening, are covered in our article on microbial testing of botanical products.

What the research can and can't tell us

The honest summary of the published literature is this: there are good mechanistic reasons to think carrier oil selection influences cannabinoid pharmacokinetics, some animal studies that support directional effects, and a relative scarcity of well-controlled human trials that quantify those effects cleanly across specific oil types and specific cannabinoids. The field is active, and a search of PubMed for "cannabinoid lipid formulation bioavailability" returns a growing body of results; but the clinical evidence base is still maturing.

That gap between mechanism and clinical evidence is worth keeping front of mind when reading formulation marketing copy. The science is real; the magnitude and practical significance of carrier-oil effects in humans, across different doses and different cannabinoid profiles, is still being worked out.

A useful habit is to ask what kind of evidence sits behind any claim. A rat study, a small pharmacokinetic study in healthy volunteers and a large controlled trial answer different questions, and a headline can blur them together. Alternative delivery approaches, such as those described in our article on nanoemulsions and water-soluble cannabinoids, face exactly the same test.

Sources

• About Medicinal Cannabis, Therapeutic Goods Administration (TGA)
• Zgair A et al., "Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines", NCBI / PubMed
• Cherniakov I et al., "Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration"; NCBI PMC
• Manufacturing quality of medicinal cannabis products, Therapeutic Goods Administration (TGA)

Tom Whitfield, Health librarian, references & fact-checking